Genmab A/S (GMAB) Reports Q2 New DARZALEX Sales of $2.88B
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- S&P 500, Dow slide after jobs report fuels rate-hike bets
- US nonfarm payrolls surge in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil heads for weekly gain as US-Iran fighting resumes; diesel hits record high
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024
July 17, 2024 6:26 AM EDTCompany Announcement
Net sales of DARZALEX® in the second quarter of 2024 totaled USD 2,878 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen)COPENHAGEN, Denmark; July 17, 2024 Genmab A/S (Nasdaq: GMAB) announced today that worldwide... More
